L-Theanine: A Comprehensive Reference Article
1. Identity and Natural Sources
Chemical Names and Structure
The chemical name N5-ethyl-L-glutamine and other synonyms for theanine reflect its chemical structure. The name theanine, without prefix, is generally understood to imply the L- (S-) enantiomer, derived from the related proteinogenic L-amino acid glutamic acid. Theanine's official chemical name is L-γ-glutamylethylamide, and "L-theanine" is a contraction of this scientific designation. The chemical structure of L-theanine is N-ethyl-L-glutamine; (2S)-2-ammonio-5-(ethylamino)-5-oxopentanoate, which was derived from the related proteinogenic L-amino acid glutamic acid.
L-theanine is a non-protein, water-soluble amino acid characteristically found in tea plants. L-theanine is an amino acid. The human body does not produce this compound, and it is not essential for humans.
Natural Sources
L-theanine exists in nature almost exclusively in Camellia sinensis, the tea plant. It is also found in trace amounts in certain mushroom species (Xerocomus badius), but tea remains the only commercially relevant natural source. Additional sources of L-theanine include C. japonica and C. sasanqua, as well as the edible mushroom Xerocomus badius.
L-theanine is biosynthesized in the roots of Camellia sinensis by the enzyme theanine synthetase, which catalyzes the condensation of glutamic acid and ethylamine. The compound is then transported upward through the plant's vascular system to the leaves and stems, where it accumulates. In the tea plant, L-theanine is the major amino acid, occurring in every organ except the fruit. The L-theanine content changes with tea cultivar and location.
The tea content of L-theanine varies markedly according to the cultivar, growth period, early versus late buds or leaves, seasonality, and brewing method. An investigation of 37 commercial varieties of tea reported an average content of 6.56 mg/g. One study noted that, contrary to popular wisdom, a standard 200 ml cup of black tea contained the most L-theanine (24.2 ± 5.7 mg), while an equivalent cup of green tea contained the least (7.9 ± 3.8 mg). L-theanine accounted for more than 50% of the amino acid fraction of the tea samples analyzed. Concentrations ranged from 0.07 mg/g of pu-erh tea to 33.37 mg/g of white tea, with wide sample variation noted among the tea varieties.
The major source of theanine is tea, containing 1.0%–2.5% of dry weight of leaves. A single cup (200 ml) of liquid tea can contain 5 to 85 mg of L-theanine depending on the type of tea. Matcha is powdered Japanese green tea where the tea powder is mixed with hot water and contains approximately 36 mg of L-theanine per serving (80 ml).
Discovery
L-theanine was discovered as a constituent of tea (Camellia sinensis) in 1949, and in 1950 a laboratory in Kyoto successfully isolated it from gyokuro leaf, which has high theanine content. The compound was named theanine, derived from an older, now abandoned scientific name for the tea plant, Thea sinensis (now known as Camellia sinensis).
Common Forms and Preparations
L-theanine can be obtained by chemical synthesis, isolation from tea (Camellia sinensis), or, more recently, through biological production by the use of specific bacterial enzymes. Artificial chemical synthesis of L-theanine (purity level ≥ 98%) uses food-grade L-glutamic acid and ethylamine with the solvent system of purified water and ethanol. Fed-batch fermentation using Escherichia coli strains engineered to express theanine synthetase has been reported in the research literature. Fermentation-derived L-theanine is chemically identical to tea-derived L-theanine.
The L-enantiomer is the form found in freshly prepared teas and in some human dietary supplements. The D-form has not been studied for safety or efficacy to the same extent as the naturally occurring L-form. Commercially, L-theanine is most commonly sold as capsules, tablets, and powder; it also appears in functional beverages, chewing gums, and as an ingredient in combination supplements.
2. Traditional and Historical Use
The ancient tradition of tea drinking was handed down by the Chinese people, who used the Camellia sinensis plant to produce soups, beverages, or infusions well known for their therapeutic properties. China has the oldest wild and planted tea trees in the world, and tea may be the first Chinese herbal medicine used by Chinese people in ancient times.
Both Chinese and Japanese traditional medicine call for the extensive use of green tea, which many East Asian cultures view as practically interchangeable with water. In ancient Japan, samurai warriors consumed matcha at tea ceremonies before battle to stay focused and relaxed, as did Zen Buddhist monks before meditation, but the compound responsible for these sought-after effects was not discovered until centuries later.
Tea preparation and consumption are especially associated with meditation and mindfulness in Buddhist religious practice. Tea was first incorporated into religious rituals during the Tang dynasty, and became closely associated with temples and monasteries. Tea is an important component of ceremonies, rituals, and religious practices all over the world, from the matcha-based Japanese tea ceremony to the Gongfu tea ceremony in China and everywhere in between. These unique traditions are often hundreds of years old and have been perfected over the course of centuries.
While scientific research has only recently caught up, tea has been used to reduce stress, promote wellbeing, and enhance cognitive function for hundreds of years. Although L-theanine per se was not identified until 1949, its psychophysiological effects are integral to the traditional use of tea in East Asian healing systems, where green tea was prepared as a hot infusion and consumed regularly for mental clarity, tranquility, and general wellness.
3. Key Active Constituents and Mechanisms of Action
Structural Analogy with Glutamate and Glutamine
Biochemically, L-theanine is a structural analogue of L-glutamate, the most important excitatory neurotransmitter of mammalian nervous systems. Recent studies suggest that L-theanine exerts neuroprotective effects by binding to and blocking glutamate receptors in the central nervous system, thus reducing excitatory impulses and lowering the stimulatory effects of glutamate. Glutamine is converted to glutamate via de-amination in the neuron mitochondria, mediated by phosphate-activated glutaminase. L-theanine inhibits the uptake of glutamine by neurons, possibly via competition for the glutamine transporter ASCT2 (SLC1A5).
Blood-Brain Barrier Penetration and Absorption
L-theanine is absorbed in the small intestine in a concentration-dependent manner and can cross the blood–brain barrier via the amino acid leucine-preferring transport system. As a structural analog of glutamate and glutamine, theanine in teas or supplements is absorbed in the small intestine after oral ingestion; its hydrolysis to L-glutamate and ethylamine occurs both in the intestine and liver, possibly functioning as a donor for glutamate synthesis.
Effects on Neurotransmitter Systems
L-theanine has been reported to stimulate production of neurotransmitters such as serotonin, dopamine, and GABA in the brain. L-theanine inhibits the glutamine transporter, thereby inhibiting the formation of glutamate from glutamine. It increases the release of GABA, whereas its effect on dopamine and serotonin levels varies depending on the area of the brain.
L-theanine is structurally similar to glutamate, the major excitatory neurotransmitter in the central nervous system, and has been shown to have micromolar affinities for glutamate receptors including the NMDA receptor. It is likely that L-theanine's mechanism is also linked to competition with glutamate at these receptors. L-theanine has been characterized as a partial agonist at the glycine binding site on NMDA receptors, suggesting a complex role in modulating excitatory neurotransmission. Regarding GABA receptors, L-theanine is noted for its ability to enhance GABAergic activity, which may contribute to its purported calming effects.
Alpha-Wave Induction
Through stimulation of the production of alpha waves in the brain, L-theanine has been reported to create a state of deep relaxation, wakefulness, and mental alertness. Some reports noted that L-theanine intake at standard supplement dosages (50–250 mg) increased alpha waves in healthy people and promoted a state of psychophysical relaxation.
Antioxidant and Anti-inflammatory Properties
The antioxidant properties of L-theanine have been attributed at least in part to its ability to reduce the synthesis of reactive oxygen species and enhance the expression and activity of antioxidant enzymes, including catalase, superoxide dismutase, and glutathione peroxidase 1. The anti-inflammatory properties of L-theanine have been associated with its ability to block the nuclear factor-κB (NF-κB) signaling pathway, thereby suppressing the expression of proinflammatory factors, including TNFα, cyclooxygenase-2, prostaglandin E2, interleukin-1β, and interleukin-6.
4. Scientific Evidence by Area of Use
4.1 Stress and Anxiety Reduction
A systematic review published in 2019 by Williams et al. found that L-theanine in its pure form at a daily dose of 200–400 mg reduced stress and anxiety in people under acute stress.
A randomized, placebo-controlled, crossover, double-blind trial examined the effects of four weeks of L-theanine administration on stress-related symptoms and cognitive functions in healthy adults. Participants were 30 individuals (nine men and 21 women; age 48.3 ± 11.9 years) who had no major psychiatric illness. L-theanine (200 mg/day) or placebo tablets were randomly and blindly assigned for four-week administration. Self-rating Depression Scale, State-Trait Anxiety Inventory-trait, and Pittsburgh Sleep Quality Index (PSQI) scores decreased after L-theanine administration (p = 0.019, 0.006, and 0.013, respectively). The PSQI subscale scores for sleep latency, sleep disturbance, and use of sleep medication also reduced after L-theanine administration, compared to placebo administration (all p < 0.05). A key limitation was the small population: the number of participants (n = 30) may have been insufficient, which is subject to type II errors.
A single dose of AlphaWave® L-theanine had significant positive effects on brainwaves, salivary cortisol, and self-reported state anxiety compared to placebo in response to an acute stress challenge. When participants received the single dose of AlphaWave® L-theanine, they responded with significantly increased frontal region alpha power during the EEG recording at 3 hours. The population enrolled did not have a clinical diagnosis of anxiety or depression; therefore, future research is needed to determine the efficacy in clinical populations. Participants were administered a 200 mg single dose and the efficacy of long-term supplementation warrants further investigation.
Kimura et al. reported significantly reduced subjective stress and anxiety response to a cognitive stressor after receiving 200 mg of L-theanine compared to placebo. This reduction in subjective stress was accompanied by a reduced stress response in secretory immunoglobulin A and heart rate, as well as a trend towards a reduction in the ratio of low frequency to high frequency components of heart rate variability, which taken together were interpreted as evidence that L-theanine administration can reduce the sympathetic nervous system response to acute stress.
In a further randomized, double-blind, placebo-controlled trial, thirty healthy adults (18–65 years) with moderate stress were randomized to AlphaWave® L-theanine (400 mg/day) or placebo (n = 15/group) for 28 days. There were no significant between-group differences in Profile of Mood States (POMS) scores. The placebo group had significant decreases in Total Mood Disturbance, Fatigue-Inertia, and Tension-Anxiety from baseline at Days 14 and 28. This mixed result illustrates the inconsistency in the literature.
Overall evidence strength for stress and anxiety: Some studies suggest L-theanine may reduce stress and anxiety, though findings are often inconsistent. Whether there is adequate mechanistic evidence or supporting information for health claims remains open to debate. The published literature on L-theanine is inconsistent, sometimes lacking appropriate rigor and reproducibility, especially in the context of the evidence from human clinical trials. The body of evidence is preliminary to moderate; most trials have small sample sizes, short durations, and industry-affiliated funding.
4.2 Sleep Quality
A systematic review and meta-analysis aimed to evaluate the effects of L-theanine on sleep outcomes by searching five electronic databases and one register (Cochrane Central Register of Controlled Trials). Randomized controlled trials investigating the effects of L-theanine supplementation on sleep quality in humans of all ages and health status were included. Nineteen articles (N = 897 participants) were selected and 18 were included in the meta-analysis.
L-theanine was shown to significantly improve subjective sleep onset latency (SMD = 0.15, 95% CI [0.01, 0.29], p = 0.04; n = 10 studies), subjective daytime dysfunction (SMD = 0.33, 95% CI [0.16, 0.49], p < 0.001; n = 9 studies), and overall subjective sleep quality score (SMD = 0.43, 95% CI [0.04, 0.83], p = 0.03; n = 12 studies). Participants took 50 mg to 1000 mg of L-theanine daily for varying periods of time. The results revealed that objective sleep measures did not improve; however, positive effects were observed on subjective measures of sleep onset latency, daytime dysfunction, and overall sleep quality. A key limitation of this review was that it assessed different products containing L-theanine and other active ingredients.
In mice, intragastric administration of L-theanine over 30 days increased acetylcholine and GABA levels in brain tissue. Both these neurotransmitters have proven roles in sleep; an increase in the release of acetylcholine is linked to REM sleep and GABA is the major inhibitory neurotransmitter in the brain.
Overall evidence strength for sleep: Modest and preliminary. Subjective sleep outcomes show small but statistically significant benefits in meta-analysis; objective polysomnographic measures show no significant improvement. Heterogeneity of products and small trial sizes limit conclusions.
4.3 Cognitive Performance (Alone and with Caffeine)
Based on five RCTs involving 148 healthy adults, L-theanine had a dose-dependent effect on cognitive function based on rapid visual information processing and recognition visual reaction time (MD: −15.20 ms; 95%-CI [−28.99; −1.41]). The effects of L-theanine were non-significant on reaction time to a simple stimulus (MD: −0.46 ms; 95% CI [−15.65; 14.73]) and in the Stroop test (MD: −37.38 ms; 95%-CI [−86.39; 11.62]). The beneficial effects of L-theanine on cognitive performance could not be confirmed by all test methods. The contradictory results could be explained by the fact that L-theanine may only affect certain cognitive domains, and by the low number of trials and the heterogeneity of test preparations.
When combined with caffeine, L-theanine may improve cognitive performance, alertness, and focus. In one study, a combination of theanine (6 mg/kg) and caffeine (6 mg/kg) led to superior shooting and cognitive performance compared to placebo (p < 0.001 for all). On the Stroop test, the caffeine + theanine condition showed significantly lower reaction times compared to caffeine alone, theanine alone, or placebo.
Evidence suggests interactive effects of the tea components caffeine and L-theanine on behaviour. A placebo-controlled, double-blind, counterbalanced, crossover study examined the effects on cerebral blood flow (CBF) and cognitive and mood outcomes using doses that more closely reflected the ratios present in tea. Twelve habitual consumers and 12 non-habitual consumers of caffeine each received 75 mg caffeine, 50 mg L-theanine, 75 mg caffeine plus 50 mg L-theanine, and placebo across four separate visits. L-theanine attenuated the rise in blood pressure following caffeine in isolation when the two were combined.
A previous meta-analysis revealed that theanine plus caffeine significantly improved alertness in the first and second hours after intake, but only after excluding data from a study deemed to be a statistical outlier. The current review revealed that the difference between the effects of theanine plus caffeine and placebo on alertness was not as conclusive as has been suggested. The previous meta-analysis revealed that theanine plus caffeine significantly improved alertness, but only after excluding the data from a study deemed to be a statistical outlier. In subsequent analysis, no adverse clinical or methodological diversity was found to justify this exclusion.
Overall evidence strength for cognition: Moderate for the caffeine + L-theanine combination; weak to preliminary for L-theanine alone. Most relevant trials are small, short-term, and limited to healthy adults.
4.4 Attention Deficit Hyperactivity Disorder (ADHD)
One proof-of-concept neuroimaging RCT examined the acute effects of L-theanine, caffeine, and their combination on sustained attention, inhibitory control, and overall cognition in boys with ADHD. L-theanine (2.5 mg/kg), caffeine (2.0 mg/kg), their combination, and a placebo were administered in a randomized four-way repeated-measures crossover to five boys (8–15 years) with ADHD. Functional MRI was performed during a Go/NoGo task and a Stop-signal task approximately 1 hour post-dose.
L-theanine improved total cognition composite in the NIH Cognition Toolbox (p = 0.040) versus placebo. Caffeine worsened and L-theanine had a trend of worsening inhibitory control. The L-theanine–caffeine combination improved total cognition composite (p = 0.041), d-prime in the Go/NoGo task (p = 0.033), and showed a trend of improvement of inhibitory control (p = 0.080). The combination was associated with decreased task-related reactivity of a brain network associated with mind wandering (the default mode network).
Overall evidence strength for ADHD: Very preliminary. The sole neuroimaging RCT involved only five participants. The preliminary evidence needs to be replicated in a larger prospective controlled clinical trial. Potential differences in therapeutic efficacy based on age and sex also need to be explored.
4.5 Schizophrenia and Schizoaffective Disorder (as Adjunct)
Ritsner et al. conducted an 8-week, randomized, double-blind, placebo-controlled, 2-center study showing that L-theanine relieved positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder, published in the Journal of Clinical Psychiatry in 2011. L-theanine augmentation to antipsychotic therapy has been reported to ameliorate positive, activation, and anxiety symptoms in schizophrenia and schizoaffective disorder patients.
Two clinical trials studied patients with major depressive disorder (n = 20) or schizophrenia/schizoaffective disorders (n = 52), and reported minimal side effects from 250–400 mg daily dosing for 8 weeks.
Overall evidence strength for schizophrenia: Preliminary. Published RCTs are small and adjunctive (meaning L-theanine was used alongside antipsychotic medication, not as a standalone therapy). Larger independent trials are needed.
4.6 Blood Pressure and Cardiovascular Effects
L-theanine has been reported to have antihypertensive effects among its range of health benefits. A study found that L-theanine reduced physiological stress responses including blood pressure in certain conditions. This blood-pressure-lowering potential, while modest, has implications for drug interactions.
Clinical trials examining the effects of L-theanine on cognitive function, blood pressure, and sleep have used doses ranging from 12–400 mg/d, with the majority of studies using 200 mg/d.
Overall evidence strength for blood pressure: Preliminary. Effects appear modest and context-dependent (e.g., attenuating caffeine-induced blood pressure rises rather than lowering resting blood pressure in normotensive individuals). Dedicated cardiovascular trials in humans are limited.
4.7 Neuroprotection
Potential neuroprotective and anti-seizure effects have been reported in animal models. Theanine has the potential to protect neurons from excesses of glutamate. Glutamate is an essential brain chemical that may be released in excess amounts with some disease conditions (e.g., amyotrophic lateral sclerosis and cerebrovascular dementia) and with brain injuries such as strokes or physical injuries. Theanine may protect against this damage by blocking glutamine entrance to cells due to the similarity in the stereochemical structures of theanine and glutamine.
Overall evidence strength for neuroprotection: Predominantly preclinical (animal and in vitro). Human clinical evidence is absent or very limited; claims cannot be translated directly from animal studies.
5. Body Systems and Health Areas
- Central Nervous System: Alpha-wave modulation, GABAergic and glutamatergic neurotransmission, dopamine and serotonin pathways, relaxation, stress reduction, neuroprotection (preclinical), schizophrenia symptom adjunct.
- Cardiovascular System: Modest antihypertensive effects; attenuation of caffeine-induced blood pressure increases.
- Sleep Architecture: Subjective improvements in sleep onset latency, daytime dysfunction, and overall sleep quality (meta-analytic evidence); no demonstrated improvement in objective polysomnographic measures.
- Immune System: It has been reported that theanine supports the immune system and may reduce plasma total cholesterol, cholesterol ester, and very-low-density lipoprotein cholesterol. These claims are not yet substantiated by large human clinical trials.
- Antioxidant/Anti-inflammatory: Preclinical evidence for NF-κB inhibition and antioxidant enzyme upregulation; no confirmed human clinical outcomes.
- Cognition/Attention: Dose-dependent effects on certain cognitive domains (visual processing, reaction time) as monotherapy; stronger evidence when combined with caffeine for alertness.
6. Dosage Forms and Dosages Reported in Studies
In Japan, L-theanine has been approved for use in all foods, with some restrictions in the case of infant foods. In the United States, the FDA considers it to be GRAS and allows its use as an ingredient in foods and beverages up to a maximum of 250 mg per serving.
Clinical trials examining the effects of L-theanine on cognitive function, blood pressure, and sleep have used doses ranging from 12–400 mg/d, with the majority of studies using 200 mg/d. A 2019 review found that around 200 to 400 mg of L-theanine per day could help to ease anxiety and stress.
Specific dosages used across published clinical trials include:
- 200 mg/day for four weeks in a crossover RCT for stress-related symptoms and cognitive function in healthy adults.
- 400 mg/day for 28 days in a placebo-controlled trial of adults with moderate stress.
- 200 mg as a single dose in a crossover study of acute stress response.
- 2.5 mg/kg body weight as a single acute dose in the pediatric ADHD neuroimaging RCT.
- 50 mg L-theanine (alone or with 75 mg caffeine) in a crossover study of cerebral blood flow and cognition.
- 250–400 mg daily for 8 weeks in clinical trials studying patients with MDD or schizophrenia/schizoaffective disorders.
- 50 mg to 1000 mg of L-theanine daily across the 18 trials included in the sleep meta-analysis (N = 897 participants).
L-theanine is available in capsule, tablet, powder, and liquid forms. It is also sold in combination with caffeine, GABA, magnesium, and various adaptogenic herbs. Current research on the optimal dosage and timing of caffeine and L-theanine supplementation suggests that a 2:1 ratio of L-theanine to caffeine is used in studies examining optimization of cognitive function.
7. Safety Considerations and Interactions
Regulatory Status
L-theanine is sold in the United States as a dietary supplement and has been granted generally recognized as safe (GRAS) status by the US Food and Drug Administration (FDA). Three branded forms of L-theanine have achieved GRAS status with the U.S. FDA. In 2003, the German Federal Institute for Risk Assessment (Bundesinstitut für Risikobewertung, BfR) objected to the addition of isolated theanine to beverages.
Toxicology
The median lethal dose (LD50) of L-theanine is suggested to be 5 g/kg. Mutagenicity and acute and subacute toxicity tests have failed to show toxicity of synthetic L-theanine. A toxicity study in rats showed no effect on behavior, morbidity, mortality, body weight, hematology, or urinalysis. In a rat toxicity study, the no-observed-adverse-effect-level was 4000 mg/kg/d, the highest dose tested.
Adverse Effects in Human Studies
Few adverse reactions have been reported; those recorded in human pharmacokinetic studies evaluating tea extracts include headache, dizziness, and gastrointestinal symptoms. In one clinical trial, 1 patient reported slight sleepiness; 2 patients reported increased duration of sleep of up to 2 hours; and 2 patients reported increased dream activity. All tolerated the medication without drop-out. Another trial reported that "L-theanine did not produce any side effects."
Potential risks are limited to allergic reaction (extremely rare) and sleepiness/increased length of sleep or increased dream activity (rare).
The evidence supporting many health claims remains limited, especially the lack of rigorous human clinical trials. While L-theanine exhibits a good safety profile based on toxicology studies, caution is warranted regarding the purported health benefits until stronger scientific substantiation emerges.
Pregnancy and Lactation
Information regarding safety and efficacy in pregnancy and lactation is lacking.
Drug Interactions
Clinical data suggest that L-theanine inhibits the stimulant effects produced by caffeine. A study found that L-theanine reduced physiological stress responses including blood pressure in certain conditions. This blood-pressure-lowering potential, while modest, has implications for drug interactions. Additive or potentiating effects with sedatives, anxiolytics, or other GABAergic agents are a theoretical concern given L-theanine's mechanism of action, but no formal interaction studies in humans have been published to quantify this risk.
HDL-cholesterol was decreased significantly in adults with major depressive disorder administered adjunctive L-theanine, a finding that warrants attention in individuals with pre-existing lipid abnormalities.
Isolated L-theanine has no documented hepatotoxicity at supplement doses, per LiverTox. This differs from concentrated green tea catechin extracts (EGCG above 800 mg/day), which have caused rare drug-induced liver injury.
Longevity of Safety Data
The longest published safety RCT for isolated L-theanine is 28 days. Long-term safety data beyond 8 weeks of daily use in humans have not been formally established in clinical trials.
References
- Frontiers in Nutrition / PMC: L-Theanine: A Unique Functional Amino Acid in Tea (Camellia sinensis L.) With Multiple Health Benefits and Food Applications
- ScienceDirect: L-theanine: A potential multifaceted natural bioactive amide as health supplement
- PMC: Characterization of L-theanine in tea extracts and synthetic products using stable isotope ratio analysis
- Wikipedia: Theanine
- PMC: L-theanine: From tea leaf to trending supplement – does the science match the hype for brain health and relaxation?
- ScienceDirect: L-theanine: From tea leaf to trending supplement – does the science match the hype for brain health and relaxation?
- PMC: Effects of L-Theanine Administration on Stress-Related Symptoms and Cognitive Functions in Healthy Adults: A Randomized Controlled Trial
- PMC: A Randomized, Triple-Blind, Placebo-Controlled, Crossover Study to Investigate the Efficacy of a Single Dose of AlphaWave® L-Theanine on Stress in a Healthy Adult Population
- PMC: Safety and Efficacy of AlphaWave® L-Theanine Supplementation for 28 Days in Healthy Adults with Moderate Stress: A Randomized, Double-Blind, Placebo-Controlled Trial
- ScienceDirect: The effects of L-theanine consumption on sleep outcomes: A systematic review and meta-analysis
- Tandfonline: Examining the effect of L-theanine on sleep: a systematic review of dietary supplementation trials
- PMC: Promising, but Not Completely Conclusive—The Effect of L-Theanine on Cognitive Performance Based on the Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Clinical Trials
- PMC: Effects of Tea or its Bioactive Compounds L-Theanine or L-Theanine plus Caffeine on Cognition, Sleep, and Mood in Healthy Participants: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- Scientific Reports: Effects of L-theanine–caffeine combination on sustained attention and inhibitory control among children with ADHD: a proof-of-concept neuroimaging RCT
- PMC: A double-blind, placebo-controlled study evaluating the effects of caffeine and L-theanine both alone and in combination on cerebral blood flow, cognition and mood
- PMC: The Cognitive-Enhancing Outcomes of Caffeine and L-theanine: A Systematic Review
- PMC: Effects of L-theanine–caffeine combination on sustained attention and inhibitory control among children with ADHD
- PMC: L-theanine: an astounding sui generis amino acid in poultry nutrition
- ScienceDirect Topics: Theanine – an overview
- PMC: Theanine modulation of monoamine metabolism visualized by derivatized imaging mass spectrometry
- Drugs.com Natural Product Database: L-Theanine Uses, Benefits & Dosage
- Alzheimer's Drug Discovery Foundation: L-Theanine Cognitive Vitality For Researchers
- FDA Briefing Document: Pharmacological Effects of L-theanine
- NutraIngredients: L-theanine: From ancient tea tradition to modern stress relief
Volver